Vagus nerve stimulation (VNS) has developed into a neuromodulatory treatment modality with anti-inflammatory potential in AD, which it exerts essentially by engaging the α7 nicotinic acetylcholine receptor (α7nAChR) on microglia and astrocytes. This evidence concerns the gene CHRNA7 and Alzheimer disease.